Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) will post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Akebia Therapeutics to post earnings of ($0.04) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. The firm had revenue of $43.65 million during the quarter, compared to the consensus estimate of $45.61 million. During the same quarter in the prior year, the business posted ($0.06) EPS. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Akebia Therapeutics Stock Performance
NASDAQ:AKBA traded up $0.03 during midday trading on Friday, reaching $1.69. 2,074,646 shares of the stock traded hands, compared to its average volume of 3,124,112. The stock has a market capitalization of $355.39 million, a P/E ratio of -8.05 and a beta of 0.77. The company has a fifty day moving average of $1.43 and a 200 day moving average of $1.29. Akebia Therapeutics has a 12 month low of $0.80 and a 12 month high of $2.48.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $7.50 price objective on shares of Akebia Therapeutics in a research note on Wednesday, October 23rd.
Check Out Our Latest Stock Analysis on AKBA
About Akebia Therapeutics
(
Get Free Report)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Read More
Before you consider Akebia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.
While Akebia Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
